Alberta Investment Management Corp Grows Stock Position in ADMA Biologics Inc (NASDAQ:ADMA)

Alberta Investment Management Corp raised its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 17.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 294,250 shares of the biotechnology company's stock after buying an additional 44,557 shares during the quarter. Alberta Investment Management Corp owned about 0.12% of ADMA Biologics worth $5,838,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Skandinaviska Enskilda Banken AB publ bought a new stake in ADMA Biologics during the 1st quarter valued at $35,000. Tsfg LLC purchased a new position in shares of ADMA Biologics in the first quarter valued at $51,000. Harvest Fund Management Co. Ltd bought a new stake in shares of ADMA Biologics during the 1st quarter valued at $52,000. Farther Finance Advisors LLC raised its stake in shares of ADMA Biologics by 1,149.1% during the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 2,505 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new stake in ADMA Biologics during the 4th quarter worth about $85,000. Hedge funds and other institutional investors own 75.68% of the company's stock.

Insider Buying and Selling at ADMA Biologics

In other news, Director Steve Elms sold 194,749 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the transaction, the director owned 87,330 shares of the company's stock, valued at $1,767,559.20. This represents a 69.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Lawrence P. Guiheen sold 20,000 shares of ADMA Biologics stock in a transaction on Monday, June 9th. The stock was sold at an average price of $20.96, for a total transaction of $419,200.00. Following the sale, the director directly owned 94,830 shares of the company's stock, valued at $1,987,636.80. This represents a 17.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 464,621 shares of company stock worth $9,644,269 over the last three months. 3.50% of the stock is owned by insiders.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $19.33 on Friday. ADMA Biologics Inc has a 52-week low of $10.21 and a 52-week high of $25.67. The stock has a fifty day moving average of $18.81 and a 200 day moving average of $18.75. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58. The firm has a market capitalization of $4.61 billion, a price-to-earnings ratio of 22.74 and a beta of 0.38.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The business had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. During the same period in the previous year, the business earned $0.08 EPS. The business's revenue was up 40.2% on a year-over-year basis. On average, research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on ADMA shares. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial boosted their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.